ReviewMechanisms of transplant tolerance induction using costimulatory blockade
Introduction
The use of reagents blocking costimulation signals proved surprisingly effective in prolonging cell and organ allograft survival in various animal models, including nonhuman primates [1]. The two groups of reagents that have been most commonly used and whose effects have been delineated in some detail in transplantation systems will be the focus of this review; namely, CTLA4Ig or monoclonal antibodies (mAbs) against CD80/CD86 (B7.1/B7.2) or CD28, aimed at interfering with the CD28/CD80/CD86 pathway, and mAbs against CD40 — or, more commonly, against CD154 — aimed at manipulating the CD40/CD154 pathway (Fig. 1). For reasons of convenience and convention, the term ‘costimulatory blockade’ will be used solely to indicate the application of such reagents, realizing that in many cases it has not been firmly established that antibody-mediated mechanisms other than blocking do not play a role.
At first, costimulatory blockade was evaluated alone for the induction of tolerance in numerous solid-organ transplantation models. Once their powerful effects became apparent, costimulation blockers were also evaluated as a component of bone marrow transplantation (BMT) regimens for inducing mixed chimerism. Since these two applications differ substantially in several aspects, they will be discussed separately.
Section snippets
The importance of costimulation during T cell interactions with antigen-presenting cells
About 30 years ago it was proposed that additional, costimulatory signals are required as well as the specific signal through the TCR to fully activate a T cell and that the blockade of such signals can lead to tolerance 2., 3., 4.. Later, classical anergy was induced in vitro by blocking antigen-presenting cell (APC) function [5]. Subsequently, it was demonstrated that such anergy can be induced by blocking CD28, the most powerful costimulatory signal known to date for CD4 T cells 6., 7.. The
The use of costimulation-blocking reagents for tolerance induction via mixed chimerism
In the models described above, costimulatory blockade was used in combination with solid organ or islet transplantation to induce hyporesponsiveness to the donor tissue. Although encouraging results have been achieved, robust tolerance — as measured by specific unresponsiveness to fully MHC-mismatched skin grafts in euthymic mice — has not been achieved with this approach (except for the combination of costimulatory blockade with rapamycin).
By contrast, it has long been known that BMT can
Conclusions
Costimulation blockade with anti-CD154 and/or CTLA4Ig exerts its powerful beneficial effects in transplant models through numerous mechanisms. Evidence for immune regulation/suppression/deviation, anergy and clonal deletion has been variably found in models relying on costimulation blockade alone and in protocols employing costimulation blockade as part of a BMT protocol. Although these mechanisms lead to impressive results in various models, it appears that only when life-long profound clonal
Update
Recent work shows that costimulation blockade is relatively inefficient in tolerizing the direct pathway of allorecognition [88]. Further evidence for regulatory cells was found in a murine model, in which ex vivo use of anti-CD154 induced suppressor cells that protected against graft-versus-host disease in vivo [89]. Sensitized T cells prevented the effects of DST+anti-CD154 in a murine heart graft model [90], potentially elucidating another factor contributing to costimulation-resistant
Acknowledgements
We thank Leo Bühler for critical review of the manuscript, and Robin Laber for expert assistance with the manuscript. This work was supported in part by National Institutes of Health grants #R01 HL49915 and #1T32 AI-07529 and by BioTransplant, Inc. (Charlestown, MA, USA).
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
References (90)
Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
Cell
(1992)- et al.
CTLA-4 regulates induction of anergy in vivo
Immunity
(2001) - et al.
Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice
Am J Transplant
(2001) - et al.
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
Immunity
(2000) - et al.
A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation
Blood
(2002) - et al.
Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade
Transplant Proc
(1999) - et al.
Mechanisms involved in the establishment of tolerance through costimulatory blockade and BMT: lack of requirement for CD40L-mediated signaling for tolerance or deletion of donor-reactive CD4+ cells
Am J Transplant
(2001) - et al.
T cell death and transplantation tolerance
Immunity
(2001) - et al.
Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice
Blood
(2001) Mixed chimerism and transplant tolerance
Immunity
(2001)
Induction of tolerance by mixed chimerism with non-myeloablative host conditioning: The importance of overcoming intrathymic alloresistance
Biol Blood Marrow Transplant
Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions
Blood
Inability to induce tolerance through direct antigen presentation
Am J Transplant
Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell
Blood
Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice
Am J Transplant
The role of T cell costimulatory activation pathways in transplant rejection
N Engl J Med
A theory of self-nonself discrimination
Science
Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection
Science
The origin and mechanism of the allograft reaction
Immunol Rev
CTLA-4 is a second receptor for the B cell activation antigen B7
J Exp Med
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
Proc Natl Acad Sci USA
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule
Science
Long-term survival of xenogeneic pancreatic islets induced by CTLA4Ig
Science
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Nature
Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy
J Clin Invest
Induction of T cell anergy in the absence of CTLA-4/B7 interaction
J Immunol
CTLA-4 is not required for induction of CD8(+) T cell anergy in vivo
J Immunol
CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
J Exp Med
Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28
J Exp Med
CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation
J Immunol
Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
J Exp Med
Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand
Transplantation
Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4+ T cells, Interferon-γ, and CTLA4
J Clin Invest
Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner
J Immunol
Skin allograft maintenance in a new synchimeric model system of tolerance
J Immunol
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
J Exp Med
CTLA4-Ig inhibits optimal T helper 2 cell development but not protective immunity or memory response to Nippostrongylus brasiliensis
Eur J Immunol
CD28 costimulation promotes the production of Th2 cytokines
J Immunol
The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo
J Clin Invest
IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways
J Immunol
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression
J Immunol
Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance
J Immunol
CTLA4Ig-induced linked regulation of allogeneic T cell responses
J Immunol
Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade
J Immunol
Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade
Transplantation
Cited by (148)
Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol
2019, Transplant ImmunologyCitation Excerpt :No patient developed de novo DSA in our study, which is consistent with previous studies showing that de novo DSA is a rare event in belatacept-treated patients [30,31]. This result is supported by experimental evidence indicating that costimulatory blockade inhibits T follicular helper cell differentiation, B cell clonal expansion, germinal center reaction and DSA formation [32,33,35]. Consistently, our data indicate a significant reduction in circulating CD4+ and CD8+ effector T cells and post-germinal center and memory B cells after conversion to belatacept.
An immunotherapeutic strategy for prolonging graft survival in mice
2015, Transplant ImmunologyNovel immunological strategies for islet transplantation
2015, Pharmacological ResearchThe Need for Immune Modulation Despite Regenerative Medicine
2014, Regenerative Medicine Applications in Organ TransplantationCTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk
2013, International ImmunopharmacologyCitation Excerpt :In composite, our data do not support the view that reverse signaling is critical to CTLA4-Ig mediated immune regulation. CTLA4-Ig has been originally developed based on the concept that specific binding to CD80/CD86 molecules expressed on DCs interrupts CD28 mediated signaling to T cells (reviewed in [4,6]) and thus can propagate the emergence of anergy [36]. This effect of CTLA4-Ig has been solidly evidenced in numerous in vitro and in vivo studies [2,37,38].